Health Care [ 6/12 ] | Biotechnology [ 43/73 ]
NASDAQ | Common Stock
Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases.
Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA.
The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis.
Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial.
Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 4, 25 | -0.34 Increased by +46.88% | 3.21 Decreased by -110.59% |
| Jun 13, 25 | -0.52 Increased by +48.00% | -1.19 Increased by +56.30% |
| Mar 5, 25 | -1.11 Decreased by -246.88% | -0.49 Decreased by -124.56% |
| Nov 7, 24 | -0.26 Increased by +57.38% | -1.22 Increased by +78.69% |
| Aug 5, 24 | -0.64 Increased by +67.68% | -1.60 Increased by +60.00% |
| May 8, 24 | -1.00 Decreased by -153.48% | -1.19 Increased by +15.97% |
| Mar 7, 24 | -0.32 Decreased by -107.22% | -0.99 Increased by +67.68% |
| Nov 14, 23 | -0.61 Increased by +54.14% | -1.69 Increased by +63.91% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 28.30 M Decreased by -38.44% | -9.18 M Increased by +46.68% | Decreased by -32.44% Increased by +13.38% |
| Mar 31, 25 | 29.38 M Decreased by -9.87% | -14.08 M Increased by +47.51% | Decreased by -47.91% Increased by +41.77% |
| Dec 31, 24 | 21.00 M Decreased by -16.26% | -30.00 M Decreased by -156.30% | Decreased by -142.88% Decreased by -206.07% |
| Sep 30, 24 | 38.81 M Decreased by -10.52% | -6.90 M Increased by +57.45% | Decreased by -17.78% Increased by +52.45% |
| Jun 30, 24 | 45.98 M Increased by +380.67% | -17.22 M Increased by +67.24% | Decreased by -37.45% Increased by +93.18% |
| Mar 31, 24 | 32.60 M Decreased by -59.11% | -26.82 M Decreased by -152.84% | Decreased by -82.27% Decreased by -229.23% |
| Dec 31, 23 | 25.08 M Decreased by -84.33% | -11.71 M Decreased by -109.98% | Decreased by -46.68% Decreased by -163.67% |
| Sep 30, 23 | 43.38 M Increased by +224.45% | -16.22 M Increased by +52.98% | Decreased by -37.40% Increased by +85.51% |